«To date we have over 350 phenotypes enrolled in our study with over 3,200 patient samples having
undergone exome sequencing.
Not exact matches
Last year, the American College of Medical Genetics published their recommendations concerning the return of «incidental findings» to patients who
undergo whole - genome or
exome sequencing in clinical settings.
Seventy - seven cases from two neoadjuvant aromatase inhibitor clinical trials
underwent next - gen sequencing (46 whole - genome, 31
exome).
This study did not disappoint: 650 of 722 cases
underwent WGS, with the remaining 72 getting
exome only.